Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers

NCT ID: NCT05981768

Last Updated: 2023-10-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-08
• Study Completion Date: 2023-09-21

Brief Summary

To assess the effect of food on the bioavailability of 3 mg cytisinicline following single-dose administration, and to evaluate the PK profile of 3 mg cytisinicline TID following multiple days of administration during Days 5-8.

Conditions

Smoking Cessation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1: Cytisinicline 3 mg Once Daily (QD), Fasting

3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fasting conditions on Day 1 (Period 1) or Day 3 (Period 2). Participants will fast overnight for at least 10 hours before cytisinicline administration and will continue to fast for 4 hours after dosing.

Group Type: EXPERIMENTAL

Cytisinicline

Intervention Type: DRUG

film-coated oral tablets containing 3 mg cytisinicline

Part 1: Cytisinicline 3 mg QD, Fed

3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fed conditions on Day 1 (Period 1) or Day 3 (Period 2). After an overnight fasting of at least 10 hours, participants will consume a standard high-fat-high-calorie meal within 30 minutes. Cytisinicline will be administered with 240 mL of water within 5 minutes after completion of the meal.

Group Type: EXPERIMENTAL

Cytisinicline

Intervention Type: DRUG

film-coated oral tablets containing 3 mg cytisinicline

Part 2: Cytisinicline 3 mg 3 Times Daily (TID)

3 mg cytisinicline tablet administered TID each day on Day 5 to 8 (Period 3) as follows: Dose 1 will be administered in the morning between 7:00 and 9:00 AM,; Dose 2 at 5 hours (±10 minutes) after Dose 1; Dose 3 at 5 hours (±10 minutes) after Dose 2. Cytisinicline will be administered on an empty stomach (cytisinicline given at least 2 hours before food or 1 hour after food).

Group Type: EXPERIMENTAL

Cytisinicline

Intervention Type: DRUG

film-coated oral tablets containing 3 mg cytisinicline

Interventions

Cytisinicline

film-coated oral tablets containing 3 mg cytisinicline

Intervention Type: DRUG

Other Intervention Names

Cytisine

Eligibility Criteria

Inclusion Criteria

1. Free written informed consent prior to any procedure required by the study.

2. Willingness to accept and comply with all study procedures and restrictions.

3. Male or female subject ≥ 18 years, at the date of signing the informed consent.

4. Regular moderate combustible cigarette smokers (self-reported average of at least 10 cigarettes per day).

5. Body mass index (BMI) of 18.0 to 30.0 kg/m^2, inclusive.

6. Healthy subject, based on medical history, physical examination, vital signs, ECG and clinical laboratory tests.

7. Negative test results for anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), Hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibodies (anti-HCVAb).

8. A female subject is eligible if she also meets one of the following criteria:

1. is of non-childbearing potential (underwent a permanent sterilization method [eg, hysterectomy, bilateral salpingectomy or bilateral oophorectomy], is clinically diagnosed infertile, or is in a post-menopausal state); or

2. is of childbearing potential and agrees to use an accepted contraceptive method from at least 4 weeks prior to admission and until at least 4 weeks after the last dose administration (Day 8).

Exclusion Criteria

AT SCREENING

1. Known hypersensitivity/allergic reaction to cytisinicline or any of the excipients.

2. Known severe hypersensitivity reaction to any other drug.

3. Any medical condition (eg, gastrointestinal, renal or hepatic, including peptic ulcer, inflammatory bowel disease or pancreatitis) or surgical condition (eg, cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion) or subject safety.

4. Stroke or acute myocardial infarction within the previous 3 months.

5. History of hyperthyroidism.

6. History of psychosis or of a psychotic event.

7. Estimated renal creatinine clearance (CLCr) below the lower limit of the normal range (ie, 90-120 mL/min/1.73 m^2 for males and 80-110 mL/min/1.73 m^2 for females), based on creatinine clearance calculation by the Cockcroft-Gault formula and normalized to an average body surface area of 1.73 m^2.

8. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper limit of the normal (ULN) range.

9. Positive result in urine drugs-of-abuse or ethanol tests at Screening.

10. Excessive caffeine consumption, defined as ≥ 800 mg per day.

11. Veins unsuitable for intravenous puncture on either arm (eg, veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).

12. Participation in any clinical trial within the previous 2 months.

13. Use of any smoking cessation medications such as cytisinicline, bupropion, varenicline, nortriptyline, or any nicotine replacement therapy (NRT; eg, nicotine patch, nicotine chewing gum, or electronic cigarettes) in the previous 8 weeks.

14. Participation in more than 2 clinical trials within the previous 12 months.

15. Blood donation or significant blood loss (≥ 450 mL) due to any reason or had plasmapheresis within the previous 2 months.

16. Female subjects who are lactating or pregnant by serum pregnancy test.

17. Any other condition that the investigator considers the subject to be unsuitable for the study.

AT ADMISSION

18. Any recent disease or condition or treatment that, according to the investigator, would put the subject at undue risk due to study participation or occurred at a time frame in which may interfere with the pharmacokinetics of study drug.

19. Use of any medicinal products, prescription and non-prescription (including vitamins, food supplements, herbal supplements [including St John's Wort]), in the previous 2 weeks, unless in the investigator's opinion the medication does not interfere with the pharmacokinetics of study drug or compromise subject safety.

NOTE: The use of topical products without systemic absorption, acetaminophen (paracetamol) at doses of ≤ 2 grams/day, and hormonal contraceptives are acceptable.

20. Use of any smoking cessation medications (eg, cytisinicline, bupropion, varenicline, nortriptyline, or any NRT eg, nicotine patch, nicotine chewing gum, or electronic cigarettes) since Screening.

21. Positive result in drugs-of-abuse or ethanol tests.

22. If female, positive pregnancy test in urine.

23. Any other condition that the investigator considers to render the subject unsuitable for the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Achieve Life Sciences

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marlene Fonseca, MD

Role: PRINCIPAL_INVESTIGATOR

Blue Clinical

Locations

BlueClinical Phase I

Porto, , Portugal

Countries

Portugal

Other Identifiers

ACH-CYT-11

Identifier Type: -

Identifier Source: org_study_id